Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
Abroad (travel likely)RecruitingPHASE2
Conditions
Head and Neck Squamous Cell Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality, China
Study leads
Yuankai Shi, MD
Principal Investigator
Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College